Nucelion Therapeutics enters into MoU with Nordic Cell Therapy Group

Denmark-based Nordic Cell Therapy Group has entered into a Memorandum of Understanding (MoU) with Hyderabad-based Nucelion Therapeutics to explore opportunities for collaboration in the cell therapy space.

The agreement establishes a framework to exchange expertise and evaluate potential areas of cooperation supporting the development and translation of advanced therapy programmes.

By bringing together complementary perspectives from scientific, translational, and industrial environments, this collaboration aims to explore ways to support innovators developing next-generation cell therapies as part of a broader international ecosystem of partners and collaborators.

Carlos Villaescusa, CEO, Nordic Cell Therapy Group said, “Building strong international collaborations is essential for advancing complex cell therapy programs. We look forward to exploring how our complementary expertise can support innovators developing next-generation therapies.”

Dr Raghu V. Malapaka, CBO, Nucelion Therapeutics said, "This collaboration represents an important step in expanding our global partnerships and strengthening our ability to support innovators developing next-generation cell and gene therapies. Our common shared goal is to make these advanced therapies more accessible and affordable and bring meaningful impact to patients worldwide.”